Cargando…
Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma
SIMPLE SUMMARY: In recent years, a number of new, effective treatments have become available for advanced renal (kidney) cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the n...
Autores principales: | Khan, Yasir, Slattery, Timothy D., Pickering, Lisa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764621/ https://www.ncbi.nlm.nih.gov/pubmed/33322163 http://dx.doi.org/10.3390/cancers12123750 |
Ejemplares similares
-
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
por: Feng, Maple Ye, et al.
Publicado: (2022) -
Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022) -
The future is now: beyond first line systemic therapy in hepatocellular carcinoma
por: Nenu, Iuliana, et al.
Publicado: (2019) -
New approaches to first-line treatment of advanced renal cell carcinoma
por: George, Daniel J., et al.
Publicado: (2021) -
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
por: Wu, Bin, et al.
Publicado: (2018)